Swiss lab finds toxic substances in Philip Morris e-cigarette
Highly toxic substances escape from the filters of IQOS electronic cigarettes produced by Swiss-based tobacco manufacturer Philip Morris International.
These dangerous toxins, called isocyanates, are released when polymer filters are heated to 100 degrees Celsius.
However, the laboratory did not check whether the substance is inhaled by the smoker.
“If isocyanates are inhaled during the use of IQOS, it is very problematic,” warns Rainer Kaelin, a pulmonologist and former vice-president of the Swiss Lung League.
Even inhaling very small amounts, he notes, can cause serious health damage.
Voluntary ban
Isocyanates can cause illness even three months after exposure. In some extreme cases, the inhalation of isocyanates into the air has “led to fatal diseases after one year”, Kaelin said.
Philip Morris acknowledges the problem, but a spokesman for the tobacco company assured the newspaper that the toxin is not inhaled when using an IQOS cigarette.
Last year Swiss producers of electronic cigarettes, and several retail outlets that sell such products agreed to a voluntary ban on the sale to minors until a Swiss law change comes into effect.
More
More
Inside Philip Morris International: On a mission to convince the skeptics
This content was published on
What is it like to work inside the world’s largest tobacco company as it tries to radically reinvent itself?
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
‘Swiss marijuana champion’ finds new markets with ‘cannabis light’
This content was published on
There’s decaffeinated coffee, alcohol-free beer, and now marijuana that doesn’t make you high. A producer reveals the hidden side of the market.
This content was published on
Addiction Switzerland calls for more research to better understand the addictive risks of new products such as electronic cigarettes.
This content was published on
The American company JUUL, which specializes in the manufacture of electronic cigarettes, is preparing to set up in the Swiss city of Zug.
E-cigarette industry agrees to voluntary sales ban for minors
This content was published on
The code of conduct from the consortium of tobacco manufacturers and large retailers will come into force on October 1. Some 38 companies have previously signed up to an earlier charter from the Swiss Vape Trade Association, which also seeks to protect minors from such products. The signatories of the latest agreement have undertaken not…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.